Core D: Biospecimens and Supplementary Measures

核心D。生物样本和实施措施总结/摘要 核心D（生物标本和补充措施）的共同主题是保存和管理ASPREE期间收集的现有生物标本和补充数据，并监督通过ASPREE-XT获得的此类数据的持续生成。这些数据涉及影响老年人健康和疾病的生物（和其他）因素，包括阿尔茨海默病和相关痴呆症（ADRD）结构病理学的神经成像，以及从患癌症的参与者中收集的肿瘤标本。核心D将确保标本、图像和其他补充数据将永久保存，以供未来合作使用;同时与其他核心密切互动，包括用于临床终点确认的核心B和用于数据管理的核心C。核心D由2个主要组成部分组成，这对U19中提出的目标的成功至关重要：（1）负责生物库生物样本，包括肿瘤组织样本;（2）访问现有神经影像数据，以评价ADRD与脑血管病理学。两国目前和未来的肿瘤组织收集将通过核心D进行管理，核心D将提供来自澳大利亚和美国生物储存库的资源和专业知识，与核心B的终点团队密切联系，负责提供癌症病例进行裁定。核心D还将监督补充措施和提供从生物标本中获得的现有数据。沿着两国管理核心，核心D将有助于生物标志物获取和样本分析的管理和决策。通过数据存储和管理与核心C合作，核心D将确保生物标志物数据传播到U19，用于与癌症，痴呆和其他结局相关的分析，包括但不限于炎症生物标志物和基因组数据（例如ADRD相关研究的APOE等位基因数据）。核心D还将管理现有纵向MRI数据的存储和访问，以识别与ADRD一致的神经退行性病理学变化与以下ASPREE子研究中收集的血管病理学变化：ENVISion（阿司匹林预防老年人认知能力下降：神经血管成像研究），SNORE成像（神经认知结果研究，阿司匹林对睡眠呼吸暂停的放射学和视网膜影响）和NEURO（LDA对脑微出血数量的影响及其与认知功能的相关性）。

CORE D. BIOSPECIMENS AND SUPPLEMENTARY MEASURES SUMMARY / ABSTRACT The common theme for Core D (Biospecimens & Supplementary Measures) is to conserve and administer existing biospecimens and supplementary data collected during ASPREE, and oversee the continued generation of such data acquired through ASPREE-XT. These data relate to biological (and other) factors that influence health and disease in aging individuals, including neuroimaging for Alzheimer’s disease and related dementia (ADRD) structural pathology, and tumor specimens collected from participants who develop cancers. Core D will ensure that the specimens, images and other supplementary data will be perpetuated for future collaborations; all the while interacting closely with other Cores including Core B for clinical endpoint confirmation and Core C for Data Management. Core D consists of 2 main components which are critical to the success of the Aims proposed in the U19: (1) responsibility for biobanked biological samples including tumor tissue samples; (2) access to data from existing neuroimages to evaluate ADRD vs cerebrovascular pathology. The current and future collections of tumor tissues across both countries will be managed through Core D, which will provide the resources and expertise from the biorepositories in Australia and the U.S., linking closely with the endpoint team in Core B, responsible for providing the cancer cases for adjudication. Core D will also provide oversight of supplementary measures and provision of existing data obtained from biospecimens. Along with the Bi-National Administrative Core, Core D will contribute to the governance and decisions about biomarker access and analyses of samples. In collaboration with Core C through data storage and management, Core D will ensure that biomarker data are disseminated to the U19 for analysis related to cancer, dementia and other outcomes and include, but are not limited to, inflammatory biomarkers and genomic data (such as APOE allele data for ADRD-related studies). Core D will also manage storage and access to the collection of existing longitudinal MRI data to identify changes in neurodegenerative pathology consistent with ADRD versus vascular pathology collected in the following ASPREE substudies: ENVISion (aspirin for the prevention of cognitive decline in the Elderly: a Neuro-Vascular Imaging Study), SNORE-imaging (Study of Neurocognitive outcomes, Radiological and retinal Effects of Aspirin in Sleep Apnea) and NEURO (effect of LDA on number of cererbral microbleeds and correlation with cognitive function).